Directed share issue in Vicore Pharma Holding AB (SE) — SEK 500 million

Carnegie acted as joint bookrunner in the directed share issue of 29,875,000 new shares at a subscription price of SEK 16.75 per share. Vicore is an innovative Swedish clinical-stage pharmaceutical company unlocking the potential of a new class of drugs to stop disease progression and restore function. The company is establishing a portfolio in rare lung diseases including idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH).